Alivus Life Sciences Q2 FY27 Share Price & Earnings Call Analysis

₹1,480.60-1.11% today
Market cap
₹18,171 Cr
P/E
29.24
ROE
17.88%
PEG
5.24
Price to sales
7.00
Debt to equity
0.02
52W high / low
₹1,521 / ₹860
Sales growth (5Y)
6.24%
EBITDA margin
32.30%
Net profit margin
21.54%
Promoter holding
74.85%
Sales (last year)
₹2,590 Cr

Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.

Guidance scorecard · Q2 FY27 call

What Alivus Life Sciences Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#67of 87 in
Pharmaceuticals & Biotechnology

RevenueQ2 FY27 call

10–20%
  • Alivus Life Sciences expects overall revenue growth of 10% to 12% for FY27.
  • They aim to double the CDMO business in 3 to 4 years, targeting it to contribute about 12% to 15% of overall revenues by then.
  • The generic API business grew 11% YoY in Q2 FY27, indicating steady organic growth.
  • New product launches and portfolio expansion in high-potent APIs (30 new products with $86 billion addressable market) support sustained growth.
  • Planned investments include building a formulation, oral solids facility within 18 to 24 months.
  • Both organic growth (through new filings and launches) and inorganic growth (careful acquisitions with API platform synergy) are being pursued.

2 more points from Alivus Life Sciences Ltd's call on revenue

Create a free account to keep reading this call

Full Q2 FY27 analysis

MarginsQ2 FY27 call

Flat

See what Alivus Life Sciences Ltd said on margins — free account, 30 seconds.

Full Q2 FY27 analysis

CapexQ2 FY27 call

Planned
  • Alivus Life Sciences plans to invest organically by building a formulation and oral solids manufacturing facility, expected to be completed in 18 to 24 months.
  • Considering inorganic growth, the company is evaluating opportunities that have clear synergies with its existing API platform to create added value.
  • They aim to enhance the CDMO portfolio by adding new platforms like IQGenX and pellets, expanding capabilities beyond API to formulations.
  • The company intends to build its own formulations manufacturing facility (especially oral solids for oncology) to protect IP and ensure quality, timing aligned with product approvals in 3 to 4 years.

2 more points from Alivus Life Sciences Ltd's call on capex

Create a free account to keep reading this call

Full Q2 FY27 analysis

FundraisingQ2 FY27 call

See what Alivus Life Sciences Ltd said on fundraising — free account, 30 seconds.

Full Q2 FY27 analysis

Order bookQ2 FY27 call

  • Alivus Life Sciences currently has 5 ongoing CDMO projects.
  • Each project typically ranges between INR 5-7 million per molecule.
  • There are several potential new projects in advanced discussions, with expectations to close a couple in the first half of next year.
  • New projects are expected to keep driving momentum and growth in CDMO business.
  • Capacity expansion with the upcoming Solapur facility will enable handling larger projects, including intermediates.

2 more points from Alivus Life Sciences Ltd's call on the order book

Create a free account to keep reading this call

Full Q2 FY27 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹18,347 Cr—
440%+Flat₹8,418 Cr32.3
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Alivus Life Sciences Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Alivus Life Sciences Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Alivus Life Sciences Ltd

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +82.85%82.85%82.85%75.00%75.00%74.99%74.94%74.91%74.91%74.87%74.87%74.85%
FIIs +4.57%5.01%4.81%7.85%6.74%6.57%6.42%6.84%5.08%5.30%5.54%5.93%
DIIs +0.74%1.41%1.57%4.16%4.86%5.19%5.62%5.47%7.13%7.27%7.18%7.03%
Public +11.84%10.73%10.76%12.99%13.40%13.25%13.03%12.79%12.89%12.55%12.42%12.19%
No. of Shareholders1,85,5311,56,1831,49,3961,43,9601,46,8401,41,9771,38,5001,35,6431,32,7481,27,9691,25,5591,22,777

Financials of Alivus Life Sciences Ltd

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +595573537589507642650602588673689640682
YoY Sales growth+17%+6%-14%+2%-15%+12%+21%+2%+16%+5%+6%+6%+16%
Expenses +428400395429373452451430409442475429417
Operating Profit167173141159134190198172179231215212265
OPM %28%30%26%27%27%30%31%29%30%34%31%33%39%
Other Income +523591010915-12232220
Interest0000001111111
Depreciation13131514151516171820202122
Profit before tax159161130150127185191163174198216212262
Tax %25%26%24%26%25%26%26%25%25%24%25%25%25%
Net Profit +1191199811195137142122130150163160197
EPS in Rs9.699.697.999.107.7811.1811.589.9110.6012.2513.2513.0416.03

Financials of Alivus Life Sciences Ltd

Profit & Loss

Annual income statement trend

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +08861,5371,8852,1232,1612,2832,3872,5522,684
Sales growth+354,468%+73%+23%+13%+2%+6%+5%+7%+8%
Expenses +06381,0641,2941,5061,5181,6081,7021,7541,762
Operating Profit-0248473592617643675684798923
OPM %-4.0%28%31%31%29%30%30%29%31%34%
Other Income +0-0110142811333453
Interest0134882812255
Depreciation0192933384253617582
Profit before tax-0228421471565629631654751888
Tax %4,200%14%26%25%26%26%25%26%25%
Net Profit +-0196313352419467471486564670
EPS in Rs-3.9118.1429.0432.6134.1738.1138.4339.6345.9954.57
Dividend Payout %0%0%0%0%61%110%59%13%11%

Financials of Alivus Life Sciences Ltd

Balance Sheet

Capital structure and asset base

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital0.01222252525252525
Reserves-1864007512,0302,1142,3082,7933,3083,607
Borrowings +000031917575753
Other Liabilities +11,3871,3241,244414545501537594658
Total Liabilities01,4751,7261,9972,4712,7022,8503,4113,9834,342
Fixed Assets +04565465735957818059551,0381,047
CWIP08011149262106102284408
Investments0000000478780986
Other Assets +09391,1691,4101,7841,8601,9391,8771,8811,901
Total Assets01,4751,7261,9972,4712,7022,8503,4113,9834,342

Financials of Alivus Life Sciences Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-010195388598306414392565
Cash from Investing Activity +0-9-51-69-122-147-116-616-570
Cash from Financing Activity +01-137-214-79-388-279-6-64
Net Cash Flow028106397-22818-230-69
Free Cash Flow-01144322466143285226259
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit4,800%14%61%84%119%71%85%81%93%

Financials of Alivus Life Sciences Ltd

Ratios

Working capital efficiency and return ratios

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days44185152120116136122148153
Inventory Days162441227214185224251237246
Days Payable4120111192110158139137132
Cash Conversion Cycle165424268241190202235248267
Working Capital Days-2,059-186-3712149176188201194
ROCE %529%186%97%42%30%28%25%24%

Guidance history

How Alivus Life Sciences Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q2 FY27 call →10–20%FlatPlanned——
Q1 FY27 call →10–20%Up 0–2%Planned—Rising
Q4 FY26 call →0–10%FlatPlanned——
Q3 FY26 call →0–10%Up 2%+Planned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

86out of 100

Momentum score · price trend

86 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,920 stocks
Last 12 months+66.3%89%
Last 6 months+32.0%84%
Last 3 months+11.3%82%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,920 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Alivus Life Sciences Ltd: 0.4 × 89 + 0.4 × 84 + 0.2 × 82 = 86.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 6 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Others in Pharmaceuticals & Biotechnology this season

  • Divis Laboratories (Q2 FY27)

    Consolidated total income: ₹3770 crores . Key results statement takeaways from Divis Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sec

  • Infinium Pharma (Q2 FY27)

    3,940.98 Lacs (about 54.3% increase) . Key results statement takeaways from Infinium Pharmachem Ltd's Q2 FY27 results statement — and how it ranks against secto

  • Walpar Nutrition (Q2 FY27)

    3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase of approximately 13.79%. Key results statement takeaways from Walp

  • Kilitch Drugs (Q2 FY27)

    14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.